| Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score HI Yang, MF Yuen, HLY Chan, KH Han, PJ Chen, DY Kim, SH Ahn, ... The lancet oncology 12 (6), 568-574, 2011 | 714 | 2011 |
| Chronic hepatitis B virus infection WK Seto, YR Lo, JM Pawlotsky, MF Yuen The Lancet 392 (10161), 2313-2324, 2018 | 582 | 2018 |
| Epidemiology of hepatocellular carcinoma in the Asia-Pacific region RX Zhu, WK Seto, CL Lai, MF Yuen Gut and liver 10 (3), 332, 2016 | 582 | 2016 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind … M Buti, E Gane, WK Seto, HLY Chan, WL Chuang, T Stepanova, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 196-206, 2016 | 527 | 2016 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non … HLY Chan, S Fung, WK Seto, WL Chuang, CY Chen, HJ Kim, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 185-195, 2016 | 515 | 2016 |
| 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection K Agarwal, M Brunetto, WK Seto, YS Lim, S Fung, P Marcellin, SH Ahn, ... Journal of hepatology 68 (4), 672-681, 2018 | 426 | 2018 |
| Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs ML Grayson, SM Crowe, JS McCarthy, J Mills, JW Mouton, SR Norrby, ... CRC press, 2010 | 393* | 2010 |
| Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study WK Seto, TSY Chan, YY Hwang, DKH Wong, J Fung, KSH Liu, H Gill, ... Journal of Clinical Oncology 32 (33), 3736-3743, 2014 | 362 | 2014 |
| Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease MF Yuen, WK Seto, DHF Chow, K Tsui, DKH Wong, VWS Ngai, ... Antiviral therapy 12 (8), 1295-1304, 2007 | 338 | 2007 |
| Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B J Fung, CL Lai, WK Seto, MF Yuen Journal of antimicrobial chemotherapy 66 (12), 2715-2725, 2011 | 290 | 2011 |
| hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection LY Mak, DKH Wong, KS Cheung, WK Seto, CL Lai, MF Yuen Alimentary pharmacology & therapeutics 47 (1), 43-54, 2018 | 247 | 2018 |
| Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study WK Seto, AJ Hui, VWS Wong, GLH Wong, KSH Liu, CL Lai, MF Yuen, ... Gut 64 (4), 667-672, 2015 | 242 | 2015 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 220 | 2022 |
| Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety MF Yuen, WK Seto, J Fung, DKH Wong, JCH Yuen, CL Lai Official journal of the American College of Gastroenterology| ACG 106 (7 …, 2011 | 209 | 2011 |
| Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma DKH Wong, FY Huang, CL Lai, RTP Poon, WK Seto, J Fung, IFN Hung, ... Hepatology 54 (3), 829-836, 2011 | 203 | 2011 |
| Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA DKH Wong, WK Seto, KS Cheung, CK Chong, FY Huang, J Fung, CL Lai, ... Liver International 37 (7), 995-1001, 2017 | 199 | 2017 |
| Reduction of covalently closed circular DNA with long-term nucleos (t) ide analogue treatment in chronic hepatitis B CL Lai, D Wong, P Ip, M Kopaniszen, WK Seto, J Fung, FY Huang, B Lee, ... Journal of hepatology 66 (2), 275-281, 2017 | 199 | 2017 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The lancet Gastroenterology & hepatology 8 (10), 879-907, 2023 | 183 | 2023 |
| Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B WK Seto, DKH Wong, J Fung, FY Huang, KSH Liu, CL Lai, MF Yuen Clinical Microbiology and Infection 20 (11), 1173-1180, 2014 | 170 | 2014 |
| Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos (t) ide analogues of different potency DKH Wong, WK Seto, J Fung, P Ip, FY Huang, CL Lai, MF Yuen Clinical gastroenterology and hepatology 11 (8), 1004-1010. e1, 2013 | 164 | 2013 |
Man-Fung YuenProfessor, Department of Medicine, The University of Hong KongZweryfikowany adres z hkucc.hku.hk
